Showing results (1-10 of 86) with videos related to
Sort By:
Pageof 9
Antimicrobial Agents and Chemotherapy|May 9, 2018
A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility TestingPatricia A Bradford, Michael D Huband, Gregory G StoneAntimicrobial Agents and Chemotherapy|October 8, 2014
In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniaeStephan A Kohlhoff, Michael D Huband, Margaret R HammerschlagAntimicrobial Agents and Chemotherapy|January 11, 2017
Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United StatesHelio S Sader, Michael D Huband, Mariana Castanheira, et al.Antimicrobial Agents and Chemotherapy|February 20, 2020
Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018Michael A Pfaller, Michael D Huband, Dee Shortridge, et al.Journal of Global Antimicrobial Resistance|November 14, 2021
Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY Antimicrobial Surveillance Program, 2019Michael A Pfaller, Michael D Huband, Dee Shortridge, et al.Antimicrobial Agents and Chemotherapy|January 31, 2018
Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance ProgramMichael A Pfaller, Michael D Huband, Dee Shortridge, et al.Journal of Global Antimicrobial Resistance|March 3, 2019
Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017Michael D Huband, Michael A Pfaller, Dee Shortridge, et al.Antimicrobial Agents and Chemotherapy|June 28, 2017
Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant EnterobacteriaceaeMariana Castanheira, Michael D Huband, Rodrigo E Mendes, et al.The Pediatric Infectious Disease Journal|December 6, 2017
Ceftazidime-Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011-2015)Helio S Sader, Michael D Huband, Leonard R Duncan, et al.International Journal of Antimicrobial Agents|March 1, 2017
Impact of defined cell envelope mutations in Escherichia coli on the in vitro antibacterial activity of avibactam/β-lactam combinationsSarah M McLeod, Sara A Patey, Michael D Huband, et al.Pageof 9